Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)
- 229 Downloads
Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).
Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity.
Twenty-seven patients, including 17 with SLE (6 with SLE/Sjögren’s syndrome), were analyzed retrospectively. Twenty-three patients (85 %) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p < 0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 %, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p < 0.0001).
CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.
KeywordsSystemic lupus erythematosus Cutaneous lupus erythematosus Hydroxychloroquine Cutaneous lupus erythematosus disease area and severity index (CLASI)
A part of this work was supported by grants from the Ministry of Welfare and Education, Culture, Sports, Science, and Technology of Japan (T.I.). We appreciate Professor Victoria P. Werth (Philadelphia VAMC and University of Pennsylvania, Department of Dermatology) for reviewing this manuscript.
Conflict of interest
The Japanese Hydroxychloroquine Study Group is a volunteer initiative to develop HCQ in Japan and does not have any conflicts of interest. For the preparation of the clinical trial of HCQ, N.Y. and F.F. gave a lecture to Sanofi Aventis KK (lecture fee <US $1,000).
- 1.Yokogawa N. Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/anti-rheumatic drugs; 10. Hydroxychloroquine. Nihon Naika Gakkai Zasshi. 2011;100:2960–5 (in Japanese).Google Scholar
- 2.Kishimoto M, Deshpande GA, Yokogawa N, Buyon JP, Okada M. Hydroxychloroquine in Japan: a newly rising sun. J Rheumatol. 2012 (in press).Google Scholar
- 4.Yokogawa N, Kato Y, Sugii S, Inada S. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol. 2011 [Epub ahead of print].Google Scholar
- 5.Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol. 2011 [Epub ahead of print].Google Scholar
- 7.Sontheimer RD, McCauliffe DP. Lupus-specific skin disease (cutaneous LE). In: Wallace DJ, Hahn WB, editors. Dubois’ lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 576–620.Google Scholar
- 15.Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2011 [Epub ahead of print].Google Scholar